(CercleFinance.com) – UCB gains almost 2% in Brussels, benefiting in particular from an analysis by Deutsche Bank which announced today that it had raised its recommendation on the title of the Belgian biopharmaceutical group, going from ‘hold’ to ‘buy’ ‘ with a target price raised from 85 to 100 euros.
In a research note, the analyst explains that its increase comes after the ‘solid’ results published for the first half of the year and before the highly anticipated decision of the American FDA on the approval of Bimzelx in the treatment of psoriasis, planned for here at the end of September.
If he notes that this meeting is not without risk given the postponements of product launches which may have punctuated the history of the laboratory, the intermediary considers that the rest of the file is relatively low risk.
The market indeed expects modest beginnings for Bimzelx, he argues, adding that a certain skepticism surrounds the achievement of the 2025 objectives while the catalysts which are looming on the horizon 2024, notably in lupus, are underestimated by the market.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
